Valuation: argenx SE

Capitalization 42.98B 50.65B 39.37B 37.12B 69.23B 4,826B 69.78B 467B 182B 2,298B 190B 186B 7,954B P/E ratio 2026 *
28.7x
P/E ratio 2027 * 22x
Enterprise value 38.37B 45.21B 35.14B 33.13B 61.79B 4,308B 62.29B 417B 163B 2,052B 170B 166B 7,100B EV / Sales 2026 *
7.55x
EV / Sales 2027 * 5.88x
Free-Float
100%
Yield 2026 *
-
Yield 2027 * 0.12%
1 day+3.04%
1 week+0.99%
Current month+3.47%
1 month+1.35%
3 months-1.37%
6 months-9.36%
Current year-3.57%
1 week 661.2
Extreme 661.2
716.4
1 month 646
Extreme 646
721
Current year 568.4
Extreme 568.4
738
1 year 456.6
Extreme 456.6
810
3 years 271
Extreme 271
810
5 years 201.4
Extreme 201.4
810
10 years 10.15
Extreme 10.15
810
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2026
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Chairman 54 06/05/2026
Director/Board Member 76 13/05/2015
Director/Board Member 65 28/04/2016
Change 5d. change 1-year change 3-years change Capi.($)
+3.04%+0.99%+39.35%+87.67% 49.1B
+1.80%-0.76%+84.08%+63.24% 47.65B
-0.83%-6.05%+0.61%-9.01% 23.8B
+2.51%-25.80%+59.63%+448.23% 21.97B
+1.22%+0.06%+43.12%-26.94% 17.26B
+1.07%-2.07%+25.78%-39.30% 15.88B
-2.01%-3.31%+55.66%+195.39% 15.77B
+3.21%+9.89%-22.12%+869.35% 14.03B
+0.45%-4.30%+39.94% - 13.32B
+3.22%+12.54%+37.43%+156.90% 12.11B
Average +1.37%-1.56%+36.35%+193.95% 23.09B
Weighted average by Cap. +1.59%-2.09%+43.18%+151.87%

Financials

2026 *2027 *
Net sales 5.08B 5.99B 4.65B 4.39B 8.18B 570B 8.25B 55.16B 21.53B 272B 22.46B 21.98B 940B 6.19B 7.29B 5.66B 5.34B 9.96B 694B 10.04B 67.18B 26.22B 331B 27.35B 26.77B 1,145B
Net income 1.52B 1.79B 1.39B 1.31B 2.44B 170B 2.46B 16.48B 6.43B 81.16B 6.71B 6.57B 281B 2.07B 2.44B 1.9B 1.79B 3.34B 233B 3.36B 22.51B 8.79B 111B 9.16B 8.97B 384B
Net Debt -4.62B -5.44B -4.23B -3.99B -7.43B -518B -7.49B -50.13B -19.57B -247B -20.41B -19.98B -854B -6.6B -7.78B -6.05B -5.7B -10.63B -741B -10.72B -71.72B -27.99B -353B -29.2B -28.58B -1,222B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
11/05/26 691.20 +3.04% 94,808
08/05/26 670.80 -0.06% 94,098
07/05/26 671.20 -2.50% 110,846
06/05/26 688.40 +1.44% 90,590
05/05/26 678.60 -0.85% 84,716
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
691.20EUR
Average target price
846.01EUR
Spread / Average Target
+22.40%

Quarterly revenue - Rate of surprise